H19 and chronic myelogenous leukemia, BCR-ABL1 positive: It is therefore thought that the disruption of H19 expression along with imatinib treatment would be a promising therapeutic strategy to combat CML, as the combination of these two could trigger leukemic cells to undergo apoptosis.